HBV Elimination Global Resource Center

Helping Global Providers Stay on the Cutting Edge of HBV and HDV Care to Advance Elimination

Module #1

Optimizing Global Screening and Treatment Efforts to Mitigate HBV Morbidity and Mortality Video

Hear expert insights on strategies to eliminate HBV and explore opportunities for closing gaps across the care continuum!

0.75-hour CME/CE | HBV Micro-Learning Video Library

Persistent gaps across the HBV care continuum point to urgent needs to drastically scale up HBV screening, prevention, and treatment, particularly among underserved communities who bear the highest disease burden. Tune in to this video as global hepatitis experts exchange ideas about ways to accelerate HBV elimination across different regions by optimizing patient outreach, testing, prevention, antiviral treatment, and monitoring.

Module #2

Uncovering Key Advances in HDV Management: Where Do We Stand Today?

Gain valuable insights from experts about HDV infection and how to optimize care for your patients.

0.5-hour CME/CE | Micro-Learning Video Library (Part 2 of 5)

Hepatitis D virus (HDV) infection among people with HBV has been associated with increased risk of cirrhosis, hepatocellular carcinoma, and worsened liver function. Despite significant research, there are a multitude of unknowns related to global HDV prevalence and optimal approaches for screening and management.

Tune in to this video as renowned hepatitis clinicians discuss the most up-to-date information about global HDV burden, diagnosis, and new and emerging treatment options.

Module #3

Pursuing Functional Cure in HBV: What's New?

Learn the latest in hepatitis B treatment strategies and help close gaps in care.

0.25-hour CME/CE | HBV Micro-Learning Video Library (Part 3 of 5)

New leaps in global hepatitis B (HBV) research provide hope that HBV cure is within reach. Emerging treatments have the potential to improve patient outcomes and bring us closer to the functional cure of the virus. Tune in to this video to learn more about the role that emerging therapeutic strategies will play in ongoing HBV elimination efforts and to hear prominent HBV clinicians interpret the latest findings from pivotal clinical trials. This expert-led discussion will include:

  • Recognizing advances toward achieving HBV elimination, identifying remaining gaps in global and national efforts, and exploring opportunities to close gaps across the care continuum
  • Evaluating the latest clinical data on emerging therapeutic strategies for achieving a functional cure of chronic HBV infection

Module #4

Addressing Stigma and Social Determinants of Health to Improve HBV Outcomes

Addressing Stigma and Social Determinants of Health to Improve HBV Outcomes

0.5-hour CME/CE | HBV Micro-Learning Video Library (Part 4 of 5)

Stigma and discrimination associated with HBV infection, particularly among immigrants/migrants and other vulnerable populations, have been long-standing barriers to patient engagement in HBV screening, treatment, and monitoring. Tune in to this video to hear experts debate practical solutions for reducing stigma and addressing social determinants of health among underserved patient groups.

Upon completion, you will be better prepared to:

  • Recognize advances toward achieving HBV elimination, identify remaining gaps in global and national efforts, and explore opportunities for closing gaps across the care continuum
  • Incorporate evidence-based strategies for improving engagement in HBV screening and care
  • Employ interprofessional strategies to mitigate the burden of HBV-related stigma on the quality of life and health-seeking behaviors of diverse patient populations

Module #5

Global HBV Elimination: Where Do We Stand and Where Are We Headed?

Help reduce hepatitis B morbidity and mortality with practical strategies from this video

0.5-hour CME/CE | HBV Micro-Learning Video Library (Part 5 of 5)

With less than 10 years remaining in the timeline set for global viral hepatitis elimination, this is a critical moment to assess current progress toward elimination goals, pinpoint persistent gaps along the HBV care continuum, and implement culturally sensitive approaches to accelerate HBV screening and treatment programming.

Watch this video and learn to:

  • Recognize advances toward achieving HBV elimination, identify remaining gaps in global and national efforts, and explore opportunities for closing gaps across the care continuum during the COVID-19 pandemic and beyond
  • Employ interprofessional strategies to mitigate the burden of HBV-related stigma and social determinants of health on patient engagement
  • Incorporate collaborative approaches and lessons learned from the COVID-19 pandemic to optimize HBV screening and management services

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close